These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 9060620)

  • 21. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein.
    Jiang S; Lin K; Lu M
    J Virol; 1998 Dec; 72(12):10213-7. PubMed ID: 9811763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities.
    Alsmadi O; Tilley SA
    J Virol; 1998 Jan; 72(1):286-93. PubMed ID: 9420226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41.
    Rey-Cuillé MA; Svab J; Benferhat R; Krust B; Briand JP; Muller S; Hovanessian AG
    J Pharm Pharmacol; 2006 Jun; 58(6):759-67. PubMed ID: 16734977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human monoclonal antibodies to HIV-1: cross-reactions with gag and env products.
    Pollock BJ; McKenzie AS; Kemp BE; McPhee DA; D'Apice AJ
    Clin Exp Immunol; 1989 Dec; 78(3):323-8. PubMed ID: 2482145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.
    Phogat S; Svehla K; Tang M; Spadaccini A; Muller J; Mascola J; Berkower I; Wyatt R
    Virology; 2008 Mar; 373(1):72-84. PubMed ID: 18155743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of conformation-dependent anti-gp120 murine monoclonal antibodies produced by immunization with monomeric and oligomeric human immunodeficiency virus type 1 envelope proteins.
    Sugiura W; Broder CC; Moss B; Earl PL
    Virology; 1999 Feb; 254(2):257-67. PubMed ID: 9986792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cross-reactivity of anti-human immunodeficiency virus type 1 gp41 antibodies with human astrocytes and astrocytoma cell lines.
    Spehar T; Strand M
    J Virol; 1994 Oct; 68(10):6262-9. PubMed ID: 8083966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.
    Ofek G; Tang M; Sambor A; Katinger H; Mascola JR; Wyatt R; Kwong PD
    J Virol; 2004 Oct; 78(19):10724-37. PubMed ID: 15367639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region.
    Banerjee S; Shi H; Banasik M; Moon H; Lees W; Qin Y; Harley A; Shepherd A; Cho MW
    Virology; 2017 May; 505():113-126. PubMed ID: 28237764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viremic HIV infected individuals with high CD4 T cells and functional envelope proteins show anti-gp41 antibodies with unique specificity and function.
    Curriu M; Fausther-Bovendo H; Pernas M; Massanella M; Carrillo J; Cabrera C; López-Galíndez C; Clotet B; Debré P; Vieillard V; Blanco J
    PLoS One; 2012; 7(2):e30330. PubMed ID: 22312424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.
    Derby NR; Gray S; Wayner E; Campogan D; Vlahogiannis G; Kraft Z; Barnett SW; Srivastava IK; Stamatatos L
    Virology; 2007 Sep; 366(2):433-45. PubMed ID: 17560621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of human immunodeficiency virus type 1 glycoprotein gp120/gp41 interacting sites by the idiotypic mimicry of two monoclonal antibodies.
    Lopalco L; Longhi R; Ciccomascolo F; De Rossi A; Pelagi M; Andronico F; Moore JP; Schulz T; Beretta A; Siccardi AG
    AIDS Res Hum Retroviruses; 1993 Jan; 9(1):33-9. PubMed ID: 7678970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular mimicry accompanying HIV-1 infection: human monoclonal antibodies that bind to gp41 and to astrocytes.
    Eddleston M; de La Torre JC; Xu JY; Dorfman N; Notkins A; Zolla-Pazner S; Oldstone MB
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):939-44. PubMed ID: 7506553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.
    Benjouad A; Gluckman JC; Montagnier L; Bahraoui E
    J Virol; 1993 Mar; 67(3):1693-7. PubMed ID: 7679751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.
    Edinger AL; Ahuja M; Sung T; Baxter KC; Haggarty B; Doms RW; Hoxie JA
    J Virol; 2000 Sep; 74(17):7922-35. PubMed ID: 10933700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.
    Choudhry V; Zhang MY; Sidorov IA; Louis JM; Harris I; Dimitrov AS; Bouma P; Cham F; Choudhary A; Rybak SM; Fouts T; Montefiori DC; Broder CC; Quinnan GV; Dimitrov DS
    Virology; 2007 Jun; 363(1):79-90. PubMed ID: 17306322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
    McCaffrey RA; Saunders C; Hensel M; Stamatatos L
    J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.